Ahmed Hosney Nada, Ismail A Ibrahim, Vittorio Oteri, Laila Shalabi, Nada Khalid Asar, Saja Rami Aqeilan, Wael Hafez
{"title":"脐带间充质干细胞治疗1型和2型糖尿病的安全性和有效性：一项系统回顾和荟萃分析","authors":"Ahmed Hosney Nada, Ismail A Ibrahim, Vittorio Oteri, Laila Shalabi, Nada Khalid Asar, Saja Rami Aqeilan, Wael Hafez","doi":"10.1080/17446651.2025.2457474","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Many patients struggle to control glucose without side effects. Due to their immunomodulatory and regenerative properties, mesenchymal stem cells (MSCs) might treat Diabetes Mellitus (DM). The authors employed this meta-analysis to evaluate the efficacy and safety of umbilical cord MSCs (UCMSCs) for DM management.</p><p><strong>Methods: </strong>The PubMed, Cochrane, WOS, Embase, and Scopus databases were searched for randomized controlled trials (RCTs) investigating the effects of UCMSCs on DM (Types 1, 2) till January 2024. Patient demographics, interventions, and outcomes, including glycated hemoglobin (HbA1c%), C-peptide levels, and insulin requirements, were extracted. A comprehensive meta-analysis software was used.</p><p><strong>Results: </strong>Eight CTs of 334 patients (172 experimental and 162 controls) were included. UMSCs treatment substantially lowered HbA1c levels (MD = -1.06, 95% CI [-1.27, -0.85], <i>p</i> < 0.00001) with consistent outcomes (i<sup>2</sup> = 0%, <i>p</i> = 0.43). Fasting C-peptide levels were heterogeneous but favored placebo (MD = 0.35, 95% CI [0.15, 0.56], <i>p</i> = 0.0007). In T1D patients, daily insulin requirements decreased considerably (MD = -0.24, 95% CI [-0.29, -0.18], <i>p</i> < 0.00001), with heterogeneity addressed by sensitivity analysis.</p><p><strong>Conclusion: </strong>UMSCs therapy reduced HbA1c and insulin requirements, and increased C-peptide levels. Multicenter clinical trials are required to confirm the long-term efficacy and safety of UMSC therapy.</p>","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"107-117"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and efficacy of umbilical cord mesenchymal stem cells in the treatment of type 1 and type 2 diabetes mellitus: a systematic review and meta-analysis.\",\"authors\":\"Ahmed Hosney Nada, Ismail A Ibrahim, Vittorio Oteri, Laila Shalabi, Nada Khalid Asar, Saja Rami Aqeilan, Wael Hafez\",\"doi\":\"10.1080/17446651.2025.2457474\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Many patients struggle to control glucose without side effects. Due to their immunomodulatory and regenerative properties, mesenchymal stem cells (MSCs) might treat Diabetes Mellitus (DM). The authors employed this meta-analysis to evaluate the efficacy and safety of umbilical cord MSCs (UCMSCs) for DM management.</p><p><strong>Methods: </strong>The PubMed, Cochrane, WOS, Embase, and Scopus databases were searched for randomized controlled trials (RCTs) investigating the effects of UCMSCs on DM (Types 1, 2) till January 2024. Patient demographics, interventions, and outcomes, including glycated hemoglobin (HbA1c%), C-peptide levels, and insulin requirements, were extracted. A comprehensive meta-analysis software was used.</p><p><strong>Results: </strong>Eight CTs of 334 patients (172 experimental and 162 controls) were included. UMSCs treatment substantially lowered HbA1c levels (MD = -1.06, 95% CI [-1.27, -0.85], <i>p</i> < 0.00001) with consistent outcomes (i<sup>2</sup> = 0%, <i>p</i> = 0.43). Fasting C-peptide levels were heterogeneous but favored placebo (MD = 0.35, 95% CI [0.15, 0.56], <i>p</i> = 0.0007). In T1D patients, daily insulin requirements decreased considerably (MD = -0.24, 95% CI [-0.29, -0.18], <i>p</i> < 0.00001), with heterogeneity addressed by sensitivity analysis.</p><p><strong>Conclusion: </strong>UMSCs therapy reduced HbA1c and insulin requirements, and increased C-peptide levels. Multicenter clinical trials are required to confirm the long-term efficacy and safety of UMSC therapy.</p>\",\"PeriodicalId\":12107,\"journal\":{\"name\":\"Expert Review of Endocrinology & Metabolism\",\"volume\":\" \",\"pages\":\"107-117\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Endocrinology & Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17446651.2025.2457474\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17446651.2025.2457474","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
导言：许多患者在没有副作用的情况下努力控制血糖。由于其免疫调节和再生特性，间充质干细胞可能治疗糖尿病（DM）。作者采用这一荟萃分析来评估脐带间充质干细胞（UCMSCs）治疗糖尿病的有效性和安全性。方法：检索PubMed、Cochrane、WOS、Embase和Scopus数据库，检索截至2024年1月研究UCMSCs对糖尿病（1、2型）影响的随机对照试验（rct）。提取患者的人口统计资料、干预措施和结果，包括糖化血红蛋白（HbA1c%）、c肽水平和胰岛素需求。采用综合meta分析软件。结果：共纳入8组ct，共334例患者（实验组172例，对照组162例）。UMSCs治疗显著降低了HbA1c水平（MD = -1.06, 95% CI [-1.27, -0.85], p 2 = 0%, p = 0.43）。空腹c肽水平是异质性的，但对安慰剂有利（MD = 0.35, 95% CI [0.15, 0.56], p = 0.0007）。在T1D患者中，每日胰岛素需求显著降低（MD = -0.24, 95% CI [-0.29, -0.18], p）。结论：UMSCs治疗降低了HbA1c和胰岛素需求，并增加了c肽水平。需要多中心临床试验来证实UMSC治疗的长期疗效和安全性。
Safety and efficacy of umbilical cord mesenchymal stem cells in the treatment of type 1 and type 2 diabetes mellitus: a systematic review and meta-analysis.
Introduction: Many patients struggle to control glucose without side effects. Due to their immunomodulatory and regenerative properties, mesenchymal stem cells (MSCs) might treat Diabetes Mellitus (DM). The authors employed this meta-analysis to evaluate the efficacy and safety of umbilical cord MSCs (UCMSCs) for DM management.
Methods: The PubMed, Cochrane, WOS, Embase, and Scopus databases were searched for randomized controlled trials (RCTs) investigating the effects of UCMSCs on DM (Types 1, 2) till January 2024. Patient demographics, interventions, and outcomes, including glycated hemoglobin (HbA1c%), C-peptide levels, and insulin requirements, were extracted. A comprehensive meta-analysis software was used.
Results: Eight CTs of 334 patients (172 experimental and 162 controls) were included. UMSCs treatment substantially lowered HbA1c levels (MD = -1.06, 95% CI [-1.27, -0.85], p < 0.00001) with consistent outcomes (i2 = 0%, p = 0.43). Fasting C-peptide levels were heterogeneous but favored placebo (MD = 0.35, 95% CI [0.15, 0.56], p = 0.0007). In T1D patients, daily insulin requirements decreased considerably (MD = -0.24, 95% CI [-0.29, -0.18], p < 0.00001), with heterogeneity addressed by sensitivity analysis.
Conclusion: UMSCs therapy reduced HbA1c and insulin requirements, and increased C-peptide levels. Multicenter clinical trials are required to confirm the long-term efficacy and safety of UMSC therapy.
期刊介绍：
Implicated in a plethora of regulatory dysfunctions involving growth and development, metabolism, electrolyte balances and reproduction, endocrine disruption is one of the highest priority research topics in the world. As a result, we are now in a position to better detect, characterize and overcome the damage mediated by adverse interaction with the endocrine system. Expert Review of Endocrinology and Metabolism (ISSN 1744-6651), provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism, with a focus on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
